A blood-based study to predict the efficacy of carboplatin plus pemetrexed treatment on nonsquamous non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008476

Enrollment

350

Registered

2012-07-25

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonsquamous non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients intended to be treated with carboplatin and pemetrexed are eligible for this study if they meet the following criteria; 1) Patients with pathologically proven nonsquamous non-small cell lung cancer 2) Patients with stage IIIA, IIIB or IV who are not candidates for curative radiotherapy or surgery. 3) previously untreated patients 4) Patient who has at least one or more measurable lesion by RECIST. 5) Patients aged 20 years or older. 6) Adequate organ function. 7) Patients who are considered to survive for more than 3 months. 8) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Previous radiotherapy to primary lung cancer. 2) With active double cancer. 3) Patients whose participation in the trial is judged to be inappropriate due to phychological disorders.

Design outcomes

Primary

Measure	Time frame
proteomics microRNA analysis	—

Countries

Japan

Outcome results